Trials / Conditions / Unresectable Extrahepatic Bile Duct Cancer

Unresectable Extrahepatic Bile Duct Cancer

19 registered clinical trials studyying Unresectable Extrahepatic Bile Duct Cancer.

Status	Trial	Sponsor	Phase
Completed	CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery NCT01766219	Wake Forest University Health Sciences	Phase 1 / Phase 2
Withdrawn	Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duc NCT01859182	National Cancer Institute (NCI)	Phase 2
Completed	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499	University of Chicago	Phase 1
Terminated	Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333	National Cancer Institute (NCI)	Phase 1
Terminated	Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers NCT01229111	National Cancer Institute (NCI)	Phase 2
Completed	Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery NCT00553332	National Cancer Institute (NCI)	Phase 2
Terminated	Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer Th NCT00478140	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors NCT00356889	National Cancer Institute (NCI)	Phase 2
Completed	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma NCT00238212	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer NCT00107536	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot B NCT00101036	National Cancer Institute (NCI)	Phase 2
Terminated	EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191	National Cancer Institute (NCI)	N/A
Terminated	Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Du NCT00085410	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer NCT00033462	National Cancer Institute (NCI)	Phase 2
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Terminated	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer NCT00023946	National Cancer Institute (NCI)	Phase 2
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1
Withdrawn	Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating NCT00253617	Jonsson Comprehensive Cancer Center	Phase 3